Eli Lilly Acquires Orna Therapeutics
Analysis based on 13 articles · First reported Feb 09, 2026 · Last updated Feb 09, 2026
The acquisition of Orna Therapeutics by Eli Lilly and Company is expected to positively impact the biotechnology and pharmaceutical markets by advancing genetic medicine and cell therapies, particularly for autoimmune diseases. This strategic move could lead to new treatment options and further innovation in the sector, potentially boosting investor confidence in companies focused on advanced therapeutic platforms.
Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, a biotechnology company specializing in engineered circular RNA and in vivo cell engineering, for up to $2.4 billion in cash. This acquisition aims to expand Eli Lilly and Company's capabilities in genetic medicine and in vivo cell engineering, with a focus on advancing in vivo CAR-T therapies for B cell-driven autoimmune diseases. Orna Therapeutics's lead program, ORN-252, is a clinical trial-ready CD19-targeting in vivo CAR-T therapy. The circular RNA platform is anticipated to offer more durable expression of therapeutic proteins, potentially enabling treatments not feasible with current RNA or cell therapy platforms. The deal includes an upfront payment and subsequent payments based on clinical development milestones. Paul, Weiss, Rifkind, Wharton & Garrison LLP is legal counsel to Eli Lilly and Company, while Lazard and Goodwin Procter LLP are financial and legal advisors, respectively, to Orna Therapeutics.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard